Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linezolid versus vancomycin for empirical treatment of diabetic foot osteomyelitis
IRCT20150721023282N30Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diabetic foot osteomyelitis (DFO) comparing Linezolid + meropenem with Vancomycin + meropenem (2 arms). Primary endpoint: Clinical response. Started Sep 2025; status: completed.
02
Drugs
linezolidvancomycinmeropenem
03
Conditions
diabetic foot osteomyelitis (DFO)
Beyond the preview
Go deeper on IRCT20150721023282N30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150721023282N30.